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A B S T R A C T
In 2012, the FORS system was accepted by the International Society of Blood Transfusion as the 31st blood group
system. Forssman (Fs) antigen (Ag) expression is most commonly found on sheep red blood cells (RBC) but rare
in human RBC. Anti-Fs antibodies (Ab) are naturally occurring in human sera and are predominantly IgM but
they can also be IgG. To this day, the global prevalence of the FORS system is unknown. Currently, there is a lack
of natural FORS1-positive RBC available to use for anti-Fs screening in large populations. This study was de-
signed to produce FORS1-positive cells viable for 40 days use in the anti-Fs screening.
Three to 5% FORS1-positive cells were produced using sheep's blood and CellStab stabilizer solution. The
quality of the FORS1-positive cells was investigated in more than three independent experiments of ABO ti-
tration, osmotic fragility test and supernatant haemolysis. For each batch of FORS1-positive cells produced, an
extended antibody panel was performed. To demonstrate that the FORS1-positive cells can be used for up to
40 days, anti-Fs screening and classification were carried out in a patient and donor population.
Antigenic expression and membrane integrity of FORS1-positive cells remained stable for 40 days. Good
FORS1 Ag preservation was established, and minimal haemolysis was observed.
In conclusion, a novel and easy-to-produce reagent has been developed and submitted to a patent with stable
FORS1 Ag expression. With this FORS1-positive cell suspension, it is now possible to screen and classify anti-Fs
Ab in large populations.
1. Introduction
Human blood group antigens (Ag) and antibodies (Ab) are of major
importance in science transfusion in terms of allogeneic blood trans-
fusions, haemolytic transfusion reactions and foetal-maternal blood
group incompatibility. In addition, the human blood group systems and
their Ag also play an integral part in organ transplantation and are
useful markers in genetic linkage analysis. Likewise, blood groups, Ab
have the ability to mediate red blood cells (RBC) haemolysis. Such
adverse events vary from acute, delayed, intravascular and extra-
vascular haemolysis depending on the nature of the Ab. Moreover, if the
Ab are capable of crossing the placental barrier between mother and
foetus, life-threatening disease known as haemolytic disease of the
foetus, and newborn (HDFN) may occur (Daniels and Reid, 2010).
Presently, there are 36 blood group systems recognized by the
International Society of Blood Transfusion (ISBT). These systems re-
present over 300 blood group Ag, all successfully cloned and sequenced
to date. Amongst the 36 blood group systems Ag, there are 17 Ag whose
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functional importance and clinical significance in transfusion medicine
remain undetermined. This includes the recently accepted histo-blood
group system: FORS (Mitra et al., 2014).
The Forssman (Fs) Ag was first described in 1911 when John
Forssman injected a kidney tissue suspension from a guinea pig into
rabbits. This resulted in the production of Ab, which haemolysed sheep
RBC. He found that injecting the kidney tissue suspension into other
species, e.g. cows, did not produce the same Ab capable of sheep RBC
haemolysis. This Ag expressed on the surface of sheep erythrocytes was
later named the Forssman Ag (Forssman, 1911; Jesus et al., 2018).
Later, in 1987, individuals from three unrelated English families
were reported to belong to a rare A subgroup, named Apae. RBC from
Apae individuals demonstrated unusual Ab reaction patterns, strongly
reacting with Helix pomatia lectin, weakly reacting with polyclonal anti-
A reagent and non-reactive to a monoclonal anti-A Ab. Genetic and
biochemical investigations by Svensson et al. showed that the Fs gly-
colipid, most commonly found only in the RBC of non-primate animals,
was strongly expressed on RBC of Apae individuals, hence the discovery
of Fs glycolipid expression on human RBC (Svensson et al., 2013).
Once the findings by Svensson et al. fulfilled the ISBT criteria to
define a new blood group, it resulted in the abolishment of the Apae
subgroup and acceptance of FORS as the 31st blood group system in
2012 (Svensson et al., 2013). The FORS system, therefore, consists of a
single low-prevalence allele which expresses the FORS1 Ag (Yamamoto
et al., 2017).
The human Fs gene, GBGT1, composed of 7 exons and located on
chromosome 9 of the human genome (Brito et al., 2017), encodes for
the Fs glycolipid synthase, a glycosyltransferase enzyme that catalyses
Fs Ag synthesis. Humans and primates normally lack Fs synthase ac-
tivity and are therefore considered Fs Ag-negative species (Yamamoto
et al., 2017). The rare expression of the FORS1 Ag on human RBC is as a
result of an enzyme activating amino acid substitution occurring from a
missense mutation in the GBGT1 gene (Brito et al., 2017). There are two
mutations that result in the restoration of Fs synthase activity in hu-
mans, 688A > G and 887G > A. However, it was shown that the
missense mutation, 887G > A, is present in all Apae individuals
(Kaczmarek et al., 2014). The SNP, 887G > A, results in glutamine to
arginine substitution at position 296 (Arg296Gln). Due to this sub-
stitution, the inactive human Fs synthase becomes enzymatically active.
Fs synthase activity is restored, thus enabling the synthesis of the Fs Ag
(Jesus et al., 2018; Svensson et al., 2013; Yamamoto et al., 2017; Brito
et al., 2017). Inheritance of Arg296Gln is therefore linked to Fs Ag
expression and phenotype in Apae individuals (Svensson et al., 2013).
The expression of the FORS1 Ag on RBC varies amongst species
which may be divided into Fs-positive and Fs-negative. Fs-positive
species include sheep, dogs (i.e. canines), guinea pigs, hamsters and
horses, while Fs-negative species include rabbits and pigs. There are
also other species, for example, chickens and now also humans who
express the FORS1 Ag on both RBC and tissue (Forssman, 1911; Jesus
et al., 2018). This is due to the varied activity of the Fs synthase enzyme
depending on the animal species. Its activity is usually inactive in hu-
mans. In sheep, Fs synthase activity is restricted to erythroid tissue
only. In cows, rats and primates, the enzyme is completely inactive due
to point mutations or exon loss. In contrast, in a number of species
including dogs, mice, chickens, turtles and carp, the enzyme Fs synthase
is active in most tissues (Kaczmarek et al., 2014). Interestingly, the level
Fig. 1. Diagram of natural Fs antigen glycolipid, synthetic Forssman pentasaccharide kodecyte (FSL-FORS1) and Forssman disaccharide kodecyte (FSL-Fsdi). Figure
taken from Barr et al., 2015.
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of FORS1 Ag expression on canine RBC is serologically equal to human
FORS1-positive RBC. Nevertheless, sheep RBC still possess the highest
level of FORS1 Ag expression (Barr et al., 2015).
Presently, there is a lack of natural FORS1-positive RBC commer-
cially available in the market (Barr et al., 2015). Until today, studies on
the FORS blood group system have been conducted using red cell units
collected from the known Apae individuals, as performed by Svensson
et al. Canine RBC known to have similar levels of FORS1 Ag expression
as Fs human RBC have been used in the study of monoclonal anti-A
reagent activity against the FORS1 Ag. Alternatively, a modification
tool known as Kode Technology has been applied in the synthesis of
RBC to express rare antigens, e.g. the FORS1 Ag (Barr et al., 2015).
FORS kodecytes have been produced using synthetic pentasaccharide
Forssman FSL constructs – FORS1-kodecytes, and disaccharide For-
ssman FSL constructs – Fsdi-kodecytes.
The human FORS1 Ag glycolipid is structurally identical to FSL-
FORS1 construct, differing by approx. 2-nm only due to the spacer
component and possessing a different lipid tail once the natural FORS1
glycolipid is a pentasaccharide linked to a ceramide lipid tail while the
FSL-FORS1 has identical Ag (pentasaccharide) structure but with dio-
leoylphosphatidylethanolamine as the lipid tail. Kode technology en-
abled Barr et al. to synthesize FORS1 and Fsdi-kodecytes and investigate
its activity against monoclonal ABO reagents showing that anti-A re-
agents do not agglutinate FORS1 Ag-positive RBC, also allowing the
attachment of FORS1 and Fsdi antigens to solid surfaces for im-
munoassays (Fig. 1) (Barr et al., 2015).
Despite the many applications and simplicity in technique to create
kodecytes using FSL constructs, limitations to Kode Technology still
remain. Firstly, the increased cost of Forssman FSL constructs from
KODE Biotech Materials is a limiting factor to its widespread use.
Following this, the optimisation of technique for attachment of
Forssman FSL builds to RBC is challenging. A working FSL construct
stock solution is needed, that is different for each construct (Korchagina
and Henry, 2015). The typical working concentrations of FSL constructs
is 10–100 μg/mL but specific concentrations for each FSL glycan must
first be determined experimentally.
Another substantial hindrance in its use to further study the FORS
blood group is the fact that FSL modification of cells is only temporary.
RBC can only retain the FSL constructs on its cell surface when stored in
a lipid-free media (Korchagina and Henry, 2015). When kodecytes are
exposed to a lipid-containing medium, for example, plasma/serum, the
FSL constructs gradually elute from the RBC surface (Blake et al., 2011).
In general, within 24 h of kodecyte production, the level of FSL con-
structs present on the cell surface will have decreased dramatically.
Moreover, after three days, the FSL constructs are completely lost from
the kodecyte surface and are undetectable (Korchagina and Henry,
2015).
Therefore, despite the robust nature of kodecytes, the surface
modification tool is non-permanent. Due to this limitation, the
screening of plasma samples for anti-Fs in a large population using
FORS kodecytes is restricted (Korchagina and Henry, 2015; Henry et al.,
2017).
Anti-Fs Ab are naturally occurring in human sera predominantly of
IgM class but may also be IgG (Jesus et al., 2018). Thus anti-Fs Ab may
have significant implications in transfusion practice, particularly in
pregnancy and organ transplantation with its ability to induce in-
travascular haemolysis of RBC with FORS1 Ag expression (Brito et al.,
2017). Furthermore, as anti-Fs antibodies are naturally occurring, its
prevalence is high in humans (Jesus et al., 2018).
Currently, the worldwide incidence of the FORS blood group system
is unknown, and its implications in transfusion medicine have not yet
been fully determined; in order to screen for the presence of anti-Fs Ab
in large populations, readily available, easy to produce and cost-effec-
tive FORS1-positive cells are required. The absence of such cells is a
significant limiting factor in determining the worldwide prevalence of
FORS. Our aim was to produce FORS1-positive cells from sheep's blood
ready to use, with viability of up to 40 days.
2. Materials and methods
To prepare FORS1-positive cells and conduct anti-Fs screening and
classification, sheep's blood was obtained from the School of
Agriculture of Coimbra (ESAC). According to the literature, sheep
species are included amongst the known Fs-positive species (Jesus
et al., 2018). The high expression of the FORS1 Ag on the surface of
sheep erythrocytes renders sheep's blood suitable for use as FORS1-
positive cells.
2.1. Sheep blood collection
A veterinarian collected sheep's blood from the jugular vein into
several 6.0 mL BD Vacutainer EDTA tubes (BD Vacutainer, Plymouth,
UK). Once the sheep blood was collected at different days and from
different animals, an immediate ABO group and screen was performed
on-site for each batch of FORS1-positive cells, using anti-A, anti-B and
anti-AB anti-sera. This is to allow the collection of sheep's blood lacking
ABO antigenic expression.
2.2. FORSCells production
The preparation of a 3–5% FORS1-positive cell suspension first re-
quired the washing of the collected sheep's blood. One mL of whole
sheep's blood was added to a 12 × 75 mm plastic tube. NaCl 0.9% (B.
Braun Ecoflac, Lisboa, Portugal) was added and filled to the top of the
tube. Tubes were centrifuged at 1000g for five minutes. The super-
natant was decanted, and the above steps were repeated four times.
After the washing step, 250 μL of washed sheep's RBC was added to
10 mL of CellStab - Glycine buffered saline solution (Diamed ID-
Cellstab) stabilizer solution (Bio-Rad Diamed, Cressier Fr, Switzerland)
creating a 3–5% FORS1-positive cell suspension which was stored at
4 °C. Once these cells were prepared to do the Fs screening by golden
standard technique (tube), the RBC concentration selected was 3–5% as
well as associated with the smaller size of sheep's RBC (Adili et al.,
2016; Diez-Silva et al., 2010). Plasma from an Apae individual and
monoclonal anti-Fs antibody (M1/22.25.8HL cell line supernatant) was
used as negative and positive control, respectively.
For each batch of FORS1-positive cells collected and prepared in this
study, an extended Ab panel investigation was performed in which each
reagent was used according to the guidelines of the commercial house,
saline at RT, saline at 37 °C or in AGH. This was done to determine the
antigenic expression on the sheep RBC that would cause potential in-
terferences in the anti-Fs screening of patients and donor plasma. The
Ab panel consisted of the major human blood group antigens from ABO,
Rh, Kell, Duffy, Kidd, MNS, Lutheran, P1PK and Lewis systems tested by
tube technique using the 3–5% FORS1-positive cell suspension. Anti-H
lectin (Ulex europeus) and Anti-A1 lectin (Dolichos biflorus) anti-sera
were also included in the extended antibody panel. The reagents used
are identified in Table 1. The standard tube technique was employed as
opposed to the gel column agglutination technique with LISS/Coombs
ID-Gelcards (Bio-Rad Diamed, Cressier Fr, Switzerland) once sheep RBC
is smaller in diameter in comparison to human RBC. The width of sheep
RBC is approximately 5–6 μm, (Adili et al., 2016) while human RBC is
about 7.5 to 8.7 μm in diameter (Diez-Silva et al., 2010). Due to this
significant difference in size, false-negative results could be obtained if
the gel card system was used. Standard tube technique methodology,
therefore, decreased the chances of any false-negative results. Each
anti-sera was tested according to the manufacturer's instructions
against the 3–5% FORS1-positive cells. The antibody panel was per-
formed for each batch of sheep's blood collection (Table 2).
For all the experiments, each batch of FORS1 positive cells was
tested three times unless otherwise specified.
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2.3. FORSCells antigen stability test
For a period of 40 days, an Ab titration between FORS1-positive
cells and plasma from four ABO donors was conducted. Donor plasma
samples were stored in small fractions for single-use and stored at
−80 °C, during the study time. The purpose of this titration was to
determine whether there is a change in the strength of reaction between
anti-Fs in donor plasma and FORS1-positive cells; this way, RBC sta-
bility was possible to evaluate. This, in turn, determines the preserva-
tion of FORS1 Ag expression on the FORS1-positive cells. A total of four
donor plasma samples were obtained from Hospital and University
Center of Coimbra each obtained from a Group A, B, AB and O donor.
Three independent replicates of the Ab titration were performed,
The titration for each ABO plasma was conducted under two sepa-
rate conditions: in sodium chloride (NaCl) at RT and 37 °C with AHG.
Six successive plasma dilutions were prepared, i.e. 1/2, 1/4, 1/8, 1/16,
1/32, 1/64. Two hundred μL of saline was added to each tube, and then
200 μL of donor's plasma was added to the first tube (1/2 dilution). The
solution was mixed, and 200 μL were transferred from the 1st tube to
the 2nd tube. This process was repeated until the last tube in the dilution
series was reached. From this set of tubes, 100 μL of each dilution was
transferred to a new tube each correctly labelled and identified. 50 μL
of FORS1-positive cells were added to all tubes. One set of dilution
series was incubated at RT and the other at 37 °C for one hour. After
incubation, one drop of AHG reagent (Anti-Human Globulin Anti-IgG
and Anti-C3d polyspecific, Bio-Rad, Cressier, Switzerland) was added to
the dilution series, mixed and centrifuged at 1000g for one minute. All
tubes were investigated for an agglutination reaction macroscopically
using an agglutinoscope. Any weak or negative reactions were
confirmed microscopically. This procedure was performed daily over
40 days, except on weekends (27 measurements), using the same
plasma from the four ABO donors against the same FORS1-positive cells
(Advancing_Transfusion_and_celular_therapies_Worldwide_AABB,
2002).
2.4. FORSCells membrane resistance test
When the osmotic resistance is reduced, intravascular haemolysis
occurs, leading to a reduced RBC lifespan. Hence the osmotic fragility
test (OFT) is used in the diagnosis of various haematological disorders,
for example, hereditary spherocytosis, elliptocytosis, haemolytic
anaemia, glucose-6-phosphate dehydrogenase deficiency and sickle cell
anaemia. The test is conventionally performed by exposing RBC to a
hypotonic solution and measuring the intensity of light at 540 nm
transmitted through the haemoglobin solution produced due to cell
lysis (Walski et al., 2014).
Seven dilution series of saline and distilled water (H2O) were pre-
pared in the following concentrations: 100% 80%; 70%; 50%; 30%;
20% and 0% with a total volume of 1000 μL per test tube. From each
dilution, 150 μL of the solution was transferred to a microtube. To the
microtube, 50 μL of FORS1-positive cells were added. This was repeated
three times. Contents of the microtubes were homogenised by inver-
sion, incubated for 10 min at RT and centrifuged at 1000g for 3 min.
Subsequently, 200 μL of the supernatant was transferred to a 96-well
plate and read in the spectrophotometer (Shenzhen Midray Bio-Medical
Electronics CO, Hamburg, Germany) for absorbance.
The wavelength used to measure the absorbance of the supernatant
was 492/630 nm. The OFT of FORS1-positive cells was measured once
every second day (except weekends) over a period of 40 days (reaching
a total of 16 measurements). This was done to elucidate the viability of
the cells for that duration. Three independent replicates of the mea-
surements were carried out (Fig. 3).
2.5. FORSCells haemolysis test
The level of haemolysis from the supernatant of the FORS1-positive
cells solution was measured at the same time as the OFT, i.e. once every
second day for 40 days. This was performed in order to assess the de-
gradation of the FORS1-positive cells over a period of 40 days. A vo-
lume of FORS1-positive cells was kept in the fridge at 4 °C in a test tube
allowing the RBC to deposit. Two days later, 200 μL of the supernatant
was transferred to a 96-well plate, and absorbance was measured in the
spectrophotometer (Shenzhen Midray Bio-Medical Electronics CO,
Hamburg, Germany). The wavelength used for absorbance of the su-
pernatant was 492/630 nm. Similarly, three replicates of supernatant
haemolysis were performed.
After the FORS1-positive cells were proven to remain intact for
40 days from the three experiments, the FORS1-positive cells were
ready for use to screen patient and donor plasma samples for the pre-
sence of anti-Fs Ab.
3. Statistical analysis
The statistical programme IBM SPSS 246 v.19 was applied for the
Table 1
Identification of reagents used in the extended antibody panel.
Reagent Type of Ab Company City Country
DiaClon Anti-A Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-B Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-AB Monoclonal IgM Bio-Rad Cressier Switzerland
Anti-A1 Lectin Monoclonal IgM Bio-Rad Cressier Switzerland
Anti-H Lectin Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-D Complete Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-C Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-c Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-E Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-e Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-K Monoclonal IgM Bio-Rad Cressier Switzerland
Anti-Fya Human IgG Bio-Rad Cressier Switzerland
Anti-Fyb Human IgG Bio-Rad Cressier Switzerland
DiaClon Anti-Jka Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-Jkb Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-M Monoclonal IgG Bio-Rad Cressier Switzerland
DiaClon Anti-N Monoclonal IgG Bio-Rad Cressier Switzerland
Anti-S Human IgG Bio-Rad Cressier Switzerland
Anti-s Human IgG Bio-Rad Cressier Switzerland
Anti-Lua Human IgG Bio-Rad Cressier Switzerland
Anti-Lub Human IgG Bio-Rad Cressier Switzerland
DiaClon Anti-P1 Monoclonal IgM Bio-Rad Cressier Switzerland
DiaClon Anti-Lea Monoclonal IgA Bio-Rad Cressier Switzerland
DiaClon Anti-Leb Monoclonal IgM Bio-Rad Cressier Switzerland
Table 2
Extended antibody panel results.
ABO Rh Kell Duffy Kidd MNS Lutheran P1PK Lewis
A B AB A1 H D C c E e K Fya Fyb Jka Jkb M N S s Lua Lub P1 Lea Leb
FORSCells 29/01/2018 - - - - - - - - - - - - - - - - - ++ +++ - - - - -
FORSCells 21/02/2018 - - - - - - - - - - - + - - - - - + +++ ++ + - - -
FORSCells 29/03/2018 - - - - - - - - - - - ++ - - - - - + +++ - - - - -
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statistical analysis of results. The evaluation of the normal distribution
of quantitative variables was done according to the Shapiro-Wilk test.
To evaluate the computation of the haemolysis values in the osmotic
fragility test over the 40 days between the three experiments it was
used the one way ANOVA test (in the case of normality of underlying
distribution and homogeneity of variances) or Kruskal-Wallis test
(otherwise). Multiple comparisons (between the three replicates) were
performed according to the Bonferroni correction. In the supernatant
spectrophotometry study, Pearson's correlation coefficient was used,
and the student's t-test for one sample was also performed. Kruskal-
Wallis test was also used to evaluate differences between all plasma
samples in each condition (NaCl and AHG) and then Mann-Whitney U
was used to compare each two plasma samples at a time.
3.1. Ethics issues
This study respected the principles of the Declaration of Helsinki.
4. Results
An extended Ab panel was performed three times for each batch of
FORS1-positive cell suspension prepared. The results are displayed in
Table 2. The three FORS1-cell suspensions lacked ABO antigenic ex-
pression with an occasional agglutination reaction to anti-Fya, anti-Lua
and anti-Lub. A consistently strong 3+ reaction was observed with the
anti-s reagent. Also, agglutination with anti-S was registered against the
three batches, although the reaction pattern was variable; these are new
findings once these blood groups were never tested for sheep or pub-
lished.
An Ab titration was performed at three separate times using three
different sheep's blood against the same ABO plasma donors Fig. 2
below portrays similar reaction patterns in each of the three experi-
ments performed. The mean measurements recorded over 40 days for
the three independent replicates resulted in being 57.30%, 81.70%,
73.20%, and 97.60% at NaCl and 63.4%, 63.4%, 51.2% and 54.3% at
AHG respectively for Group A, B, AB and O donors. By applying the
Kruskal Wallis test, there are statistically significant differences be-
tween the titration results of all plasma samples (p < .001) for either
NaCl or AGH. The Mann-Whitney U test also revealed that there are
statistically significant differences between all pairs of plasmas: A/B, A/
O, A/AB, B/O all with significance values (p < .001) for NaCl (Fig. 2A)
and the same for AGH except for the pair A/B (Fig. 2B). These results
were obtained using the lowest and more common titration observed
for each plasma donors.
The osmotic fragility of the FORS1-positive cells remained uniform
for each concentration of saline solution prepared. While changes were
observed, these changes remained consistent in the three replicates
performed. The value of the absorbance measured in the 0% saline
solution (distilled water only) was the value used to calculate the
haemolysis value, assuming that in this condition, there is 100% hae-
molysis. It was found that the mean haemolysis value for the 100%
saline solution was 2.3 ± 1 (95% CI 1.71–2.65), for 80% solution was
6.9 ± 2.9 (95% CI 5.4–8.2), for 70% was 27.9 ± 6.9 (95% CI
24.8–31.1), for 50% was 80.1 ± 6.5 (95% CI 77.1–83.1), for 30% was
95.0 ± 3.2 (95% CI 93.4–96.4) and lastly for the 20% solution was
96.7 ± 2.8 (95% CI 95.1–97.7). Also, the results obtained in each
experience are described in Table 3.
Measurement of the supernatant haemolysis was performed in order
to assess the degradation of FORS1-positive cells in CellStab stabilizer
solution over 40 days. Similarly, to the OFT, measurements were re-
corded once every second day, and three independent replicates of the
test were carried out. The absorbance of the supernatant was measured
at a wavelength of 492/630 nm. There were no changes in the hae-
molysis levels, and the percentage haemolysis remained constant at 0%
for all three replicates of supernatant absorbance.
5. Discussion
After the abolishment of the Apae subgroup and acceptance of FORS
as an independent blood group system in 2012 by the ISBT, new
questions about the FORS system have surfaced and remained un-
determined. Such items include its global incidence, implications in
transfusion medicine, transplantation and role in cancer. It is known
that the FORS1 Ag is of low prevalence, but its real impact in transfu-
sion medicine remains to be uncovered. As for anti-Fs Ab, they are
naturally occurring Ab that have the ability to cause haemolysis of
FORS1-positive RBC (Jesus et al., 2018). Thereby, and there might be
severe consequences if an Fs-positive donor unit is administered to an
individual positive for anti-Fs.
Studies on the FORS system are hindered due to the rarity of the
FORS system in humans. Only three unrelated English families are
known to express the Fs glycolipid (Svensson et al., 2013). Further-
more, there is the absence of natural RBC with FORS1 Ag expression,
thus inhibiting extensive population studies on the FORS system (Barr
et al., 2015). Kodecyte technology is the only product commercially
available in the market that enables the synthesis of RBC with Fs gly-
colipid expression. However, there are significant limitations in using
this surface modification tool. Such barriers include its cost and 24 h
RBC production. This hinders the use of FORS kodecytes in mass
Fig. 2. Mean percentage of the 27 measurements recorded over 40 days (except
weekends) for the three independent replicates of Anti-Fs titre for each ABO
plasma donor. Significant differences between the titration results of all plasma
samples (p < .001) for either NaCl or AGH were revealed when the Kruskal
Wallis test was applied. Fig. 2A: Differences between each plasma samples at
NaCl (57.30% for Group A, 81.70% for Group B, 73.20% for Group AB and
97.60% for Grupo O). There are statistically significant differences (Mann-
Whitney U test) between all pairs of plasmas: A/B, A/O, A/AB, B/O all with
significance values (p < .001) Fig. 2B: Differences between each plasma
samples at AHG (63.4%, 63.4%, 51.2% and 54.3% respectively for Group A, B,
AB and O donors). Mann-Whitney U test also revealed statistically significant
differences (p < .001) between all pairs of plasmas except for the pair A/B.
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population screening for anti-Fs.
Through this work, an RBC suspension with stable FORS1 Ag ex-
pression has been developed and submitted to patent. The FORS1-po-
sitive cells produced from sheep's blood are shown to be viable for
40 days, where its antigenic stability and membrane integrity is pre-
served. The quality and stability of the FORS1-positive cells are verified
through Ab titration, OFT and supernatant haemolysis investigations.
The results from the Ab titration against ABO plasma donors re-
vealed that the reaction patterns to the anti-Fs Ab are very similar be-
tween the three performed replicates. Reactions remained consistent in
the three independent experiments, and NaCl condition revealed higher
anti-Fs titre than AHG condition which may be due to the fact that anti-
Fs Ab are mostly IgM which reacts preferentially at room temperature
while the IgG fraction preferably reacts at 37 °C and its reaction is
enhanced at AGH medium. In addition it was observed that the plasma
sample with most anti-Fs is from O blood group and the anti-Fs always
reacted to the previous titre in the dilution series. These results,
therefore, indicate FORS1 Ag stability on the FORS1-positive cells. As
the titration was performed daily (except weekends – 27 measure-
ments) during 40 days, it is possible to conclude that the FORS1-posi-
tive cell suspension in stabilizer solution (CellStab) can maintain its
antigenic stability for at least 40 days. This enables the detection of
anti-Fs in human sera with the use of FORS1-positive cells.
Once every second day, an OFT was performed. This evaluated the
resistance of the FORS1-positive cells to haemolysis when exposed to
descending concentrations of saline (100%, 80%, 70%, 50%, 30%, 20%
and 0%). The osmotic fragility of the FORS1-positive cells remained
uniform for each concentration of the saline solution. From this it can
be concluded that the FORS1-positive cells maintain a similar pattern of
resistance to haemolysis.
The absorbance of the supernatant was measured once every second
day for 40 days to assess the degradation of the FORS1-positive cells in
CellStab stabilizer solution. Over time, the values decrease, ap-
proaching zero, with a strong and statistically significant association
(r = −0.76, p = .001). It was also verified that the values did not
deviate significantly from the null value (p > .05) which means that
there are no significant changes in haemolysis where it has remained
constant at 0%. This confirms that the sheep RBC in stabilizer solution
did not degrade over the 40 days.
From the results of the three experiments carried out, it is proven
that the FORS1-positive cell suspension produced have antigenic sta-
bility and membrane integrity of at least 40 days. Good Ag preservation
is shown through the Ab titration performed for 40 days daily. Similar
reaction patterns from the OFT is indicative of the adequate resistance
of the FORS1-positive cells to haemolysis. Lastly the supernatant hae-
molysis observed at 0% haemolysis over 40 days confirms the pre-
servation of the FORS1-positive cells in stabilizer solution. Altogether,
an easy-to-produce novel reagent with FORS1 Ag expression has been
developed which is a reliable product for anti-Fs screening in a large
population.
Beyond this, an extended antibody panel was performed in order to
determine the antigenic expression of sheep RBC. Results from the
enlarged group indicate that sheep RBC frequently expresses the s Ag
and occasionally Duffy, Lutheran and S Ag. Such antigenic expression
does not interfere with the screening of plasma samples for anti-Fs as all
donors and patients used in the study had a negative antibody screen.
Although, the anti-sera used for antigen phenotyping of sheep RBC are
developed for human RBC and thus a negative result may probably also
indicate that the anti-sera is not cross-reacting with sheep RBC. One of
the FORS1-positive cell batches collected reacted with anti-A and anti-
A1 anti-sera; hence the blood collected was from Group A sheep's blood.
As a consequence of using Group A sheep RBC, samples containing anti-
A in their plasma, i.e. Group O and Group B donors and patients, will
lead to a false-positive result for the anti-Fs screen. Due to this, this
Fig. 3. Osmotic fragility test was done in triplicate
during 40 days and the measurements were made
every second day except weekends (16 measure-
ments). The results exhibit the mean of the haemo-
lysis measurements for the three independent ex-
periments performed in replicate of the osmotic
fragility test along this period, being the summary of
Table 3 (Total column). These were obtained by the
evaluation of the computation of the haemolysis
values between the three experiments (one way
ANOVA test - in the case of normality of underlying
distribution and homogeneity of variances - or
Kruskal-Wallis test – otherwise). Also, multiple
comparisons (between the three replicates) were
performed according to the Bonferroni correction.
Table 3
Mean values (mean ± standard deviation), representative of three independent experiments (with three replicates each) and respective confidence intervals (CI) at
95% of concentrations over 40 days for haemolysis at 0% (distilled water), 20%, 30%, 50%, 70%, 80% and 100%.
Haemolysis (%)
Dilution Experiment 1 Experiment 2 Experiment 3 Total
SF% Mean ± SD CI 95% Mean ± SD CI 95% Mean ± SD CI 95% Mean ± SD CI 95%
100 (0,9% NaCl) 1,1 ± 1,2 0,3 – 1,8 2,3 ± 1,7 1,4-3,2 2,2 ± 1,7 1,3–3,1 2,3 ± 1,0 1,71-2,65
80 (0,72% NaCl) 2,3 ± 1,2 1,5–3,1 12,2 ± 4,4 9,9–14,5 7,6 ± 3,8 5,6–9,7 6,9 ± 2,9 5,4-8,2
70 (0,63% NaCl) 13,5 ± 3,3 11,5–15,6 41,7 ± 9,1 36,9–46,6 31,4 ± 10,3 25,9–36,9 27,9 ± 6,9 24,8-31,1
50 (0,45% NaCl) 70,6 ± 7,4 65,9–75,3 86,1 ± 6,8 82,5–89,8 86,4 ± 8,7 81,8-91,1 80,1 ± 6,5 77,1-83,1
30 (0,27% NaCl) 95,6 ± 4,9 92,5–97,0 95,7 ± 4,6 93,2–98,2 95,2 ± 5,4 92,3–98,1 95,0 ± 3,2 93,4-96,4
20 (0,18% NaCl) 95,3 ± 5,3 92,0–98,7 97,0 ± 4,0 94,8–99,1 97,5 ± 3,7 95,5-99,4 96,7 ± 2,8 95,1-97,7
Distilled H2O
(0,00% NaCl)
100,0 ± 0,0 100,0 ± 0,0 100,0 ± 0,0 100,0 ± 0,0
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suspension of sheep RBC was discarded and not used in the screening
and hereafter we opted to perform an immediate ABO type on-site
during sheep's blood collection with anti-A, anti-B anti-AB anti-sera.
Lately, we confirmed that the A sample was from a species of sheep
(Mondegueira - with representation ancestor the Ovis aries studery and
also Ovis aries iberica) (Dinis, 2019) different from all the others (Ovelha
Bordaleira da Serra – a specie with very remote origins, as these sheep
evolved from wild forms from the species Ovis aries palustris, Ovis mu-
simon, and Ovis aries orientalis). (Dinis, 2013).
On the other hand, we propose that in case of dubious results,
KodeTechnology should be used to clarify and to avoid unexpected
reactions observed. Also, the authors recognize a limitation with this
FORS1-positive cells regarding the expression of Galili antigen.
Therefore it is recommend, prior to use the FORSCells, do an adsorption
protocol, as published by Mayr, 2003 (Wolfgang, 2003). For example,
rabbit RBC (expressing Galili antigen) can be used for adsorption.
(Forssman, 1911).
6. Conclusion
To conclude, a suspension of natural FORS1-positive cells has been
developed that can be used in mass population screening for anti-Fs Ab.
In this way, the worldwide prevalence of the FORS system can be de-
termined using this novel reagent. Presently, there is a patent submitted
and accepted for the commercial use of FORS1-positive cells. This novel
development by the research group in Coimbra Health School enables
further studies on FORS system using a cheap, easy-to-produce and
reliable reagent. The FORS1-positive cells can be used in routine
transfusion practice in a hospital blood bank for anti-Fs screening in
patients as well as in research.
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